Patient Death Halts Intellia’s Phase 3 CRISPR Trial

Published on Fierce Biotech

A patient in Intellia’s phase 3 trial of the CRISPR therapy nex-z has died following severe liver toxicity, prompting the FDA to keep both studies on hold. The company is investigating the liver signal and developing risk mitigation steps while monitoring all previously treated patients.

👉 Read the full article: Patient dies after receiving Intellia's CRISPR therapy

Disclaimer

Images used are for illustrative purposes only and do not depict actual persons, products, or facilities. For full detail, refer to the original article via the provided link. SSCTR does not provide medical advice, and the views expressed are for educational purposes only.